Double-blind, randomized, controlled clinical trial of norfloxacin for cholera
Open Access
- 1 May 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (5) , 939-940
- https://doi.org/10.1128/aac.34.5.939
Abstract
In a double-blind, randomized clinical trial with 78 adults with acute watery diarrhea and severe dehydration, 37 subjects were positive for Vibrio cholerae. In conjunction with rehydration therapy, 13 patients received norfloxacin, 12 received trimethoprim-sulfamethoxazole (TMP-SMX), and 12 received a placebo. Norfloxacin was superior to TMP-SMX and to the placebo in reducing stool output, duration of diarrhea, fluid requirements, and vibrio excretion. TMP-SMX was no better than the placebo.This publication has 8 references indexed in Scilit:
- In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1985
- Aetiological studies on hospital in-patients with acute diarrhoea in CalcuttaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1983
- In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogensAntimicrobial Agents and Chemotherapy, 1983
- Effect of chemotherapy on the duration of diarrhoea, and on vibrio excretion by cholera patients.1971
- Controlled Comparison of Tetracycline and Furazolidone in CholeraBMJ, 1968
- Optimal antibiotic therapy in cholera.1968
- Antibiotic susceptibility testing by a standardized single disk method.1966
- ANTIBIOTIC SUSCEPTIBILITY TESTING BY A STANDARDIZED SINGLE DISK METHOD1966